PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 18, 2026Journal of Nephrology

Immunoglobulin A nephropathy—novel insights in long-term outcomes and pathophysiology leading to international guideline modification and new emerging therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMartin KleinVRVeena RobertsMJMuhammad M Javaid

Discussion

Loading...

Member takes

Overview

Long-term outcomes report poor prognosis in immunoglobulin A nephropathy, suggesting new therapeutic approaches.

Key Points

  • This research investigates the long-term outcomes and emerging therapies for immunoglobulin A nephropathy (IgAN).
  • Analysis of long-term outcomes in IgAN patients
  • Review of revised KDIGO guidelines
  • Evaluation of emerging therapies such as TRF-budesonide and complement inhibitors.
  • Comparison of treatment efficacy among different ethnicities.
  • IgAN patients with higher proteinuria and eGFR decline face worse outcomes.
  • Revised guidelines propose new risk cutoffs and treatment goals.
  • Glucocorticoid efficacy is inconsistent, especially in Caucasian patients.
  • Emerging treatments show promise and may replace traditional therapies.

Cite This Study

Klein et al. (2026) studied this question.

synapsesocial.com/papers/69e320e740886becb6540118https://doi.org/10.1093/joneph/aajaf056
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IgA Nephropathy – Current and Future Perspectives in Treatment2024
  2. 2Recent Advances in the Management of IgA Nephropathy: From Supportive Care to Targeted Therapies2026
  3. 3The outcome of IgAN: a time of reflection in the perspective of new opportunities2026
  4. 4Treatment of primary IgA nephropathy Part 2. Immune suppressive therapy2025
  5. 5Targeted Therapeutic Options Based on the Pathogenesis of IgA Nephropathy2025 · 1 citations